Senate Bill 204
115th Congress(2017-2018)
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Became Law
Amendments
Became Public Law 115-176 on May 30, 2018
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
204
Congress
115
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
checkPassed on August 3, 2017
Status
Passed
Type
Unanimous Consent
Unanimous Consent
A senator may request unanimous consent on the floor to set aside a specified rule of procedure so as to expedite proceedings. If no Senator objects, the Senate permits the action, but if any one senator objects, the request is rejected. Unanimous consent requests with only immediate effects are routinely granted, but ones affecting the floor schedule, the conditions of considering a bill or other business, or the rights of other senators, are normally not offered, or a floor leader will object to it, until all senators concerned have had an opportunity to inform the leaders that they find it acceptable.
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
Summary
Trickett Wendler Right to Try Act of 2017
This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are: (1) intended to treat a patient who has been diagnosed with a terminal illness, and (2) authorized by state law. The federal government must allow unrestricted possession and use of such treatments by patients certified by a physician as having exhausted all other treatment options.
A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment.
The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment.
The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration; and (3) not be approved, licensed, or cleared for sale under the Federal Food, Drug, or Cosmetic Act or the Public Health Service Act.
August 4, 2017
August 3, 2017
January 24, 2017
Amendments (1)
Aug 03, 2017
Agreed to in Senate
3
Sponsorship
Senate Amendment 753
In the nature of a substitute.
Agreed To
05/30/2018
Became Public Law No: 115-176.
05/30/2018
Signed by President.
05/24/2018
Presented to President.
05/22/2018
Motion to reconsider laid on the table Agreed to without objection.
05/22/2018
On passage Passed by recorded vote: 250 - 169 (Roll no. 214). (text: CR H4355-4356)
05/22/2018
Passed/agreed to in House: On passage Passed by recorded vote: 250 - 169 (Roll no. 214).(text: CR H4355-4356)
05/22/2018
On motion to recommit with instructions Failed by the Yeas and Nays: 187 - 231 (Roll no. 213).
05/22/2018
The previous question on the motion to recommit with instructions was ordered without objection.
05/22/2018
DEBATE - The House proceeded with 10 minutes of debate on the motion to recommit with instructions. The instructions contained in the motion seek to require the bill to be reported back to the House with an amendment to strike everything after section 1 and insert a completely new text.
05/22/2018
Ms. Schakowsky moved to recommit with instructions to the Committee on Energy and Commerce. (CR H4363)
05/22/2018
The previous question was ordered pursuant to the rule.
05/22/2018
DEBATE - The House proceeded with one hour of debate on S. 204.
05/22/2018
Rule provides for consideration of H.R. 5515, S. 204 and S. 2155. The resolution provides for one hour of general debate on H.R. 5515, S. 204 and S. 2155. The resolution provides for consideration of S. 2155 and S. 204 under a closed rule. Also, the resolution provides for consideration of H.R. 5515 under a structured rule and makes an amendment in the nature of a substitute consisting of the text of Rules Committee Print 115-70 considered as adopted.
05/22/2018
Considered under the provisions of rule H. Res. 905. (consideration: CR H4355-4366)
05/21/2018
Rules Committee Resolution H. Res. 905 Reported to House. Rule provides for consideration of H.R. 5515, S. 204 and S. 2155. The resolution provides for one hour of general debate on H.R. 5515, S. 204 and S. 2155. The resolution provides for consideration of S. 2155 and S. 204 under a closed rule. Also, the resolution provides for consideration of H.R. 5515 under a structured rule and makes an amendment in the nature of a substitute consisting of the text of Rules Committee Print 115-70 considered as adopted.
08/11/2017
Referred to the Subcommittee on Health.
08/04/2017
Referred to the House Committee on Energy and Commerce.
08/04/2017
Received in the House.
08/03/2017
Message on Senate action sent to the House.
08/03/2017
Passed Senate with an amendment by Unanimous Consent.
08/03/2017
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
08/03/2017
Measure laid before Senate by unanimous consent. (consideration: CR S4788-4789)
08/03/2017
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.
01/24/2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
01/24/2017
Introduced in Senate
Public Record
Record Updated
Mar 22, 2023 7:50:58 PM